ADVANCEMENT OF POTENT BROAD SPECTRUM ENTEROVIRUS THERAPEUTICS
ADVANCEMENT OF POTENT BROAD SPECTRUM ENTEROVIRUS THERAPEUTICS
批准号:
10684969
负责人:
INGRID PERSSON
金额:
$149.92万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-07-01 至 2025-06-30
关键词:
ChildContractsEnterovirusEnterovirus 68Enterovirus 71FamilyFamily PicornaviridaeHand, Foot and Mouth DiseaseMonoclonal AntibodiesNational Institute of Allergy and Infectious DiseasePhaseSmall Business Innovation Research GrantTherapeuticVaccinesVirusacute flaccid myelitismembernervous system disorderpandemic diseasepriority pathogentherapeutic development
中文摘要
这是一项第二阶段的SBIR合同,旨在开发针对肠道病毒的广谱单抗。肠道病毒引起的神经系统疾病主要发生在幼儿身上,包括急性弛缓性脊髓炎(AFM)和手足口病(HFMD)。美国目前还没有针对这些病毒的疗法或疫苗。这些病毒是微小核糖核酸病毒家族的成员,该家族是NIAID的优先病原体,因为它们具有很高的大流行潜力。
英文摘要
This is a phase II SBIR Contract to develop broad spectrum monoclonal antibodies against enteroviruses. Enteroviruses cause neurological diseases mainly in young children including acute flaccid myelitis (AFM) and Hand Foot and Mouth Disease (HFMD). There is no therapeutics against these viruses or vaccines against them approved in the US. These viruses are members of picornavirus family, a priority pathogen of NIAID because of their high pandemic potential.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Advancement of Broad Spectrum Enterovirus Antibody Therapeutics
-
批准号:10267601
-
项目类别:
-
资助金额:$29.35万
-
财政年份:2020
-
负责人:INGRID PERSSON
-
依托单位:
海外基金